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Introduction
Focal magnetic resonance guided intensity focused ultra-
sound treatment offers a novel strategy that targets the
cancer rather than the prostate in an attempt to preserve
tissue and function. Its aim is to achieve long-term cancer
control with minimal morbidity.
Materials and methods
A prospective, ethics committee approved trial was con-
ducted to determine the side effects of focal magnetic
resonance guided intensity focused ultrasound treatment
on ExAblate 2100 (InSightech). The purpose of this
study was to evaluate the safety and initial effectiveness
of focal ExAblate MRgFUS treatments for the treatment
of organ-confined low risk prostate cancer (LRPC).
22 Adult males between the age of 49 and 73 were
underwent 23 focal treatments for locally confined pros-
tate cancer. One patient underwent two treatments due
to two different foci.
Results
5 SAE’s were reported; 4 of them were treatment-related.
3 treatment-related SAE’s were acut Urinary tract symp-
toms: Were reported in the questionnaires by 9 patients
out of 23 (39%) during their last follow-up visit; 2 of them
were reported as SAE’s. Urinary Incontinence: Was
reported by 2 patien Biopsy Results after 6 months of fol-
low-up are available for 23 patients. 2 patients dropped
out of the study prior to completion of their follow-up
periods; i.e., one patient - due to gradual continuous rise
of PSA levels (with positive 6-mo biopsy in a newly
detected focus) and the second patient due to moving to
another country. At 6-mo follow-up 9 out of 23 biopsies
(39%) were positive; all of them were in newly detected
foci (from sectors that were negative at screening); 2 of
these biopsies comprised stage upgrading as compared to
baseline, (i.e., Gleason 7).
Conclusions
Focal ExAblate treatment has a promising safety profile,
however cancer localization improved is crucial for
tumor control.
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